Mon panier

Cynomolgus BAFFR / TNFRSF13C Protein, His Tag (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
BAR-C52H4-100ug
$395.00
BAR-C52H4-1mg
$2615.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    BAFFR, TNFRSF13C, BROMIX, CD268, CVID4, prolixin, BAFF-R

  • Source

    Cynomolgus BAFFR, His Tag (BAR-C52H4) is expressed from human 293 cells (HEK293). It contains AA Ser 7 - Gly 76 (Accession # XP_005567184.1).

    Request for sequence
  • Molecular Characterization

    BAFFR Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 9.1 kDa. The protein migrates as 14-23 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    BAFFR SDS-PAGE

    Cynomolgus BAFFR, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    BAFFR SEC-MALS

    The purity of Cynomolgus BAFFR, His Tag (Cat. No. BAR-C52H4) is more than 90% and the molecular weight of this protein is around 10-20 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     BAFFR ELISA

    Immobilized Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) at 1 μg/mL (100 μL/well) can bind Cynomolgus BAFFR, His Tag (Cat. No. BAR-C52H4) with a linear range of 0.4-3 ng/mL (QC tested).

    Protocol
  •  BAFFR ELISA

    Immobilized Cynomolgus BAFFR, His Tag (Cat. No. BAR-C52H4) at 1 μg/mL (100 μL/well) can bind Anti-BAFFR Antibody, Human IgG1 with a linear range of 0.1-0.8 ng/mL (Routinely tested).

    Protocol
  •  BAFFR ELISA

    Immobilized Cynomolgus BAFFR, His Tag (Cat. No. BAR-C52H4) at 1 μg/mL (100 μL/well) can bind Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) with a linear range of 0.1-2 ng/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF. B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    B-cell activating factor receptor

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    14 Détails

  • Étape de développement la plus élevée:

    NDA/BLA

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte